Menu Search
Equities

N4 Pharma PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0GO:STU

N4 Pharma PLC

Actions
  • Price (EUR)0.001
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-71.43%
  • Beta1.2873
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

N4 Pharma plc is a United Kingdom-based pre-clinical biotech company. The Company is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The Company is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.

  • Revenue in GBP (TTM)7.07k
  • Net income in GBP-1.07m
  • Incorporated1979
  • Employees4.00
  • Location
    N4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
  • Phone+44 133 269 0061
  • Fax+44 127 982 1300
  • Websitehttps://www.n4pharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.